Bortezomib for Injection 3.5 mg

Bortezomib for Injection 3.5 mg is a powder for solution used in cancer treatment. This medication, manufactured by Teva Canada Limited, is administered intravenously or subcutaneously.

Bortezomib is primarily used in the treatment of multiple myeloma and mantle cell lymphoma. It works by inhibiting proteasome activity, which can help slow the growth of cancer cells. Patients often wonder, 'What is Bortezomib used for?' It is typically prescribed as part of a combination therapy for these conditions.

Common effects of Bortezomib may include fatigue, nausea, and peripheral neuropathy. Some patients also experience diarrhea or constipation. These effects can vary in severity and may differ from person to person.

Bortezomib should be handled with care, as it is a potent medication. It is important to follow the healthcare provider's instructions for administration and storage. Patients should be monitored for signs of infection or bleeding, as this medication can affect the immune system.

Bortezomib may interact with other medications, including those that affect the liver or immune system. It is important to inform your healthcare provider about all medications you are taking. Alcohol and certain foods may also interact with Bortezomib, so it is advisable to discuss dietary restrictions with a healthcare professional.